Avid Bioservices Inc (CDMO)

[entdoc]

Steven W King, PPHM CEO since 2003, would probably love to write, "I told you so"... So I'm saying it for him! As a corporation chieftain Steve has admirers and detractors, but to has led PPHM through three Phase II clinical programs,and placed Bavituximab into PIII, while positioning another MAB a-TNT MAB, Cotara, at the starting gate of PIII trials. Steve had the wisdom to NOT sell PPHM's in-house MaB manufacturing facility when the company was in desperate financial straits, and to bring it into full cGMP compliance so it may manufacture and sell FDA approved MABs in an FDA approved facility. Prior to Peregrine, Steve worked with MAB Vascular Targeting Agents and with UT Southwestern Medical Center with the inventor of Peregrine’s anti-phospholipid technology. He has to date been wholly ethical in the company's claims for Bavituximab, not once overstating its efficacy. Best about Steve: he holds BS and MS degrees in Biology from Texas Tech University. We want him to continue exploring therapy based on the anti-phospholipid platform, and to continue thwarting attempts to hijack/steal/delay this novel new therapy.